Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Altamira Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Tinnitus|Otitis Media
Phase 2: Otitis Media|Deafness|Tinnitus|Insomnia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2006-7041-83/hah | P2 |
Not yet recruiting |
Insomnia |
2019-07-29 |
|
TACTT3 | P3 |
Completed |
Tinnitus|Otitis Media |
2017-12-28 |
|
TACTT3 | P3 |
Completed |
Tinnitus |
2017-12-28 |
39% |
AMPACT1 | P3 |
Completed |
Tinnitus|Otitis Media |
2017-01-19 |